Experimental T-Cell combo targets Hard-to-Treat leukemia
NCT ID NCT07374029
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a new approach for acute myeloid leukemia (AML) that combines a personalized vaccine made from the patient's own immune and leukemia cells, specially trained T-cells, and two standard chemotherapy drugs. The study aims to see if this combination is safe and feasible for 30 adults with AML. Participants will receive the vaccine, T-cell infusions, and standard decitabine and venetoclax therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DC/AML fusion vaccine, T-cell therapy, decitabine, venetoclax, and GM-CSF
- What this could lead to
- If successful, this could offer a new treatment option for people with acute myeloid leukemia that combines immune-boosting cells with standard chemotherapy.
- What could go wrong
- This is a very early phase 1 trial with only 30 participants, so it is primarily testing safety and feasibility. The treatment may not work, and there are risks like cytokine release syndrome and infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?